Opioid consumption data. by Wali U. Pirzada (22278071)

“…Mean percent reduction in prescription size was greater in the Orthopaedic Surgery cohort (45% versus 38%) (p = .002). …”

Prescription data. by Wali U. Pirzada (22278071)

“…Mean percent reduction in prescription size was greater in the Orthopaedic Surgery cohort (45% versus 38%) (p = .002). …”

Refill rate by surgical specialty. by Wali U. Pirzada (22278071)

“…Mean percent reduction in prescription size was greater in the Orthopaedic Surgery cohort (45% versus 38%) (p = .002). …”

Noncontinuous data on opioid use. by Wali U. Pirzada (22278071)

“…Mean percent reduction in prescription size was greater in the Orthopaedic Surgery cohort (45% versus 38%) (p = .002). …”

Genes show significant expression change in meta-analysis and their connection with Sjogren’s syndrome and thyroid cancer. by Fanyong Kong (20700261)

“…A gene in red indicates significantly increased expression in the meta-analysis, whereas a gene in blue indicates significantly decreased expression in the meta-analysis.…”

Fig 6 - by Teagan McMahon (20108036)

DDC for four anticoagulants from 2019 to 2023. by Wei Luo (80175)

“…</p><p>Results</p><p>From 2019 to 2023, the DDDs of rivaroxaban demonstrated a significant annual increase in most hospitals (<i>p</i> < 0.05). …”

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The description of games. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The description of balance training. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

Isotype control overlays. by Chen Lu (135200)

“…<div><p>Decompression sickness is a fatal disease worldwide. Therefore, to find a prophylactic modality for decompression sickness is urgently required. …”

Original uncropped blot. by Chen Lu (135200)

“…<div><p>Decompression sickness is a fatal disease worldwide. Therefore, to find a prophylactic modality for decompression sickness is urgently required. …”

Raw Data. by Chen Lu (135200)

“…<div><p>Decompression sickness is a fatal disease worldwide. Therefore, to find a prophylactic modality for decompression sickness is urgently required. …”

Identification of BM-MSCs. by Chen Lu (135200)

Comparison of ν_s measured and predicted estimates of the optimized GPR approach for (a) training, (b) validation, and (c) testing datasets. by Fahd Saeed Alakbari (10701871)